CoChat

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker

Lee, Lucy, Niu, Huifeng, Rueger, Ruediger, Igawa, Yuriko, Deutsch, Jonathan, Ishii, Nobuya, Mu, Song, Sakamoto, Yuuichiro, Busse-Reid, Rachel, Gimmi, Claude, Goelzer, Petra, De Schepper, Stefanie, Yoshimura, Yashushi, Barrett, Joanne, Ishikawa, Yuji, Weissgerber, Georges, Peck, Richard · 2009 · Clinical Cancer Research
Cited by 41

The DOI matches its Crossref record.

Abstract

Purpose: CH4987655 (RO4987655) is an orally active and highly selective small-molecule MEK inhibitor. It potently inhibits mitogen-activated protein kinase signaling pathway activation and tumor cell growth, with an in vitro IC50 of 5.2 nmol/L for inhibition of MEK1/2. Single-agent oral administration of CH4987655 resulted in complete tumor regressions in xenograft models. Experimental Design: All 40 subjects received a single oral dose followed by 72 hrs of pharmacokinetic, pharmacodynamic, and safety/tolerability assessments. The pharmacodynamics were measured by changes in phosphorylated extracellular signal-regulated kinase (pERK) levels in a surrogate tissue peripheral blood mononuclear cells ex vivo stimulated by PMA. Results: Doses of 0.5, 1, 2, 3, and 4 mg were safe and well tolerated. No clinically significant safety event was observed. A total of 26 adverse events (n = 15) were reported: 21 mild, 5 moderate, and none severe. Moderate adverse events were experienced by one subject at 1 mg (autonomic nervous system imbalance) and three subjects at 4 mg (diarrhea, abdominal pain, autonomic nervous system and acne). CH4987655 was rapidly absorbed with a tmax of ∼1 h. Exposures were dose proportional from 0.5 to 4 mg. The disposition was biphasic with a terminal t1/2 of ∼25 hr. Intersubject variability was low, 9% to 23% for Cmax and 14% to 25% for area-under-the-curve (AUC). pERK inhibition was exposure dependent and was greater than 80% inhibition at higher doses. The pharmacokinetic-pharmacodynamic relationship was characterized by an inhibitory Emax model (Emax ∼100%; IC50 40.6 ng/mL) using nonlinear mixed-effect modeling. Conclusions: A significant extent of pERK inhibition was achieved for a single dose that was considered to be safe and well tolerated in healthy volunteers. (Clin Cancer Res 2009;15(23):7368–74)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-09-1696

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 41

Metadata

Authors
Lee, L., Niu, H., Rueger, R., Igawa, Y., Deutsch, J., Ishii, N., Mu, S., Sakamoto, Y., Busse-Reid, R., Gimmi, C., Goelzer, P., De Schepper, S., Yoshimura, Y., Barrett, J., Ishikawa, Y., Weissgerber, G., & Peck, R.
Venue
Clinical Cancer Research
Published
2009-11-30
Volume
15
Issue
23
Pages
7368-7374
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2081122128
Cited by
41
References
0
FWCI
1.92
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-09-1696
The paper
Lee, L., Niu, H., Rueger, R., Igawa, Y., Deutsch, J., Ishii, N., Mu, S., Sakamoto, Y., Busse-Reid, R., Gimmi, C., Goelzer, P., De Schepper, S., Yoshimura, Y., Barrett, J., Ishikawa, Y., Weissgerber, G., & Peck, R. (2009). The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-09-1696

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.